Fostering drug hunters and entrepreneurs Succeed
- Small molecule drug discovery and development
- Enabling entrepreneurs
- Non-dilutive funding
20 years of experience in the discovery and development of new molecular entities
I am a drug discovery leader with experience in in vitro and in silico screening, hit identification, hit-to-lead optimization (including structure-based), and preclinical development.
My expertise extends to the realm of conceptualizing, designing and building custom fragment libraries for the development of high-quality new molecular entities (NMEs) and drive innovation in drug discovery.
Importantly, I have a proven track record of securing non-dilutive funding for drug development through the prestigious NIH Small Business Innovative Research (SBIR) program and various non-profit grant mechanisms, including Michael J. Fox Foundation (MJFF) for Parkinson’s Research.
Guiding clients in optimizing drug discovery and secure non-dilutive funding
As your consultant and drug discovery expert, I provide guidance and advice to both in-house teams and external CROs throughout the entire process of target to preclinical candidate selection. I facilitate strategizing, choosing, and designing experimental methods to ensure your drug discovery programs meet expected outcomes and timely deliverables.
Over the past two decades, I have advanced programs from target selection to IND enabling studies and contributed to the development of clinical candidates and approved therapy. I draw upon these experiences to optimize and streamline programs.
Demonstrated by my success in securing non-dilutive funding, I help prepare, review and submit grant applications to various funding agencies and assist with post-submission requirements.
